Back to top
more

Pacific Biosciences of California (PACB)

(Real Time Quote from BATS)

$2.46 USD

2.46
7,881,275

+0.02 (0.82%)

Updated Nov 4, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Pacific Biosciences (PACB) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.

Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -3.70% and 2.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Moumi Mondal headshot

Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?

by Moumi Mondal

In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.

Moumi Mondal headshot

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?

by Moumi Mondal

Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.

Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.06, marking a -1.9% move from the previous day.

Reasons to Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's strong product demand and continued focus on R&D raise optimism about the stock.

PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research

by Zacks Equity Research

PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies

by Zacks Equity Research

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Pacific Biosciences of California (PACB) closed at $1.75 in the latest trading session, marking a +0.57% move from the prior day.

Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Pacific Biosciences of California (PACB) closed at $1.81 in the latest trading session, marking a +0.56% move from the prior day.

PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing

by Zacks Equity Research

PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

PacBio's Stock Up on Munster Deal for Male Infertility Research

by Zacks Equity Research

PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.

Pacific Biosciences (PACB) Upgraded to Buy: Here's Why

by Zacks Equity Research

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.

Compared to Estimates, Pacific Biosciences (PACB) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 16.67% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 16.67% and 1.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.05, representing no change from its previous close.

Pacific Biosciences of California (PACB) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day's close.

PacBio's (PACB) Revio System to Boost Novogene's German Lab

by Zacks Equity Research

PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

PacBio (PACB) and Form Bio to Boost AAV Industry Development

by Zacks Equity Research

PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.